The pharmacokinetics of pegylated liposomal doxorubicin (PLD) were investigated in 17 women undergoing intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer and peritoneal carcinomatosis. HIPEC was performed immediately after completing debulking surgery, which included a number of peritonectomy procedures. PLD was injected and allowed to equilibrate in peritoneal cavity filled with 4 liters of physiological solution and stabilized at 42°C; next, the outflow line was opened and perfusion proceeded for 1 h. PLD was stable in peritoneal perfusate and plasma. During HIPEC, PLD peritoneal perfusate/plasma gradients averaged ϳ600 or >1000 for peak concentration or area under the curve. After HIPEC, PLD plasma levels remained stable or decreased. Biopsy samples of residual normal peritoneum or ovarian carcinomatosis were collected at the end of HIPEC and were shown to contain free doxorubicin. Correlating PLD decrements in peritoneal perfusate with plasma exposure to PLD or peritoneal deposition of free doxorubicin showed that the former occurred during preperfusional equilibration of PLD in peritoneal cavity, whereas the latter occurred during 1 h of perfusion. Plasma exposure to PLD correlated negatively with the number of peritonectomy procedures performed during surgery, whereas peritoneal deposition of free doxorubicin correlated positively. Taken together, these results show that PLD administered by intraoperative HIPEC undergoes limited systemic diffusion and releases active free doxorubicin in peritoneum exposed to ovarian carcinomatosis. PLD pharmacokinetics seem to be influenced by peritonectomy procedures.
Introduction
Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed to achieve early locoregional treatment and to improve survival of patients with malignant peritoneal mesothelioma or peritoneal carcinomatosis from advanced abdominopelvic tumors (Alexander et al., 2007; Verwaal et al., 2008) . Intraoperative HIPEC is performed immediately after completion of debulking surgery and consists of perfusing the abdominal cavity with large volumes of a heated medium to which one or more antitumor drugs may be added.
The rationale for HIPEC rests with a number of pharmacological factors and therapeutic goals, such as 1) the achievement of uniformly high concentrations of antitumor drugs in the abdominal cavity, such that even potential "pharmacological sanctuaries" become exposed to a tumoricidal agent, 2) the elimination of other viable elements (platelets, white blood cells, and monocytes) that could promote tumor growth through the wound-healing process, 3) the efficacy with which the peritoneum-plasma barrier prevents drug diffusion into the bloodstream, thereby minimizing toxicity that limits systemic chemotherapy, and 4) the apparent synergism between heat and many chemotherapeutics against tumor cells Urano et al., 1999; Kong et al., 2000; Witkamp et al., 2001; Harrison et al., 2008; Ceelen and Flessner, 2010) .
Limited studies suggest that intraoperative HIPEC provides longer survival than normothermic postoperative intraperitoneal chemotherapy (Elias et al., 2007; Cashin et al., 2012) ; nevertheless, intraoperative HIPEC shows limitations in efficacy and safety that are common to any kind of intraperitoneal chemotherapy. In regard to efficacy, the advantage offered by very high locoregional concentrations of drugs is counterbalanced by a limited penetration depth of the drugs in carcinomatosis nodules (Dedrick et al., 1978; Ozols et al., 1979; Los et al., 1989) . This is caused by efficient drug removal via the capillaries of tumor neoangiogenesis; accordingly, preclinical studies sug-gest that the efficacy of intraperitoneal chemotherapy could be improved by administering an angiogenesis inhibitor (Shah et al., 2009; Shah et al., 2011) . In regard to safety, there are concerns that systemic diffusion and toxicity of antitumor drugs might occur if debulking surgery involved an extensive ablation of the peritoneum-plasma barrier. Methodological problems make it difficult to establish correlations between the risk of systemic exposure and peritoneal surface area at the moment of HIPEC. The peritoneal surface area does not always correlate with body weight or surface area; moreover, there is great interindividual variability in the surface area and permeability of one peritoneal segment or another (Breborowicz et al., 1989; Albanese at al., 2009) . It has been suggested that the risk of systemic drug diffusion might be pragmatically correlated with the number of peritonectomy procedures performed during debulking surgery (de Lima Vazquez et al., 2003; Sugarbaker et al., 2011) .
Infusional therapy with the anthracycline doxorubicin is the cornerstone of many oncological regimens; unfortunately, however, clinical use of doxorubicin is limited by dose-related cardiotoxicity (Minotti et al., 2010) . Uncoated or pegylated liposomal formulations were developed to diminish cardiac exposure to doxorubicin while also preserving or even improving doxorubicin delivery in tumors. In fact, liposomes are big enough to show only limited partitioning across the regular microvasculature of heart and many other organs; on the other hand, liposomes are small enough to cross the "leaky" microvasculature of tumors and to eventually degrade for releasing free doxorubicin in close proximity to tumors cells (Minotti et al., 2004) . Doxorubicin has long been used also in the settings of HIPEC (Ozols et al., 1982; Rossi et al., 2002; de Lima Vazquez et al., 2003; Deraco et al., 2011; Sugarbaker et al., 2011) . A phase I study showed that HIPEC with pegylated liposomal doxorubicin (PLD) was also feasible, resulted in formation of very high doxorubicin peritoneal/ plasma gradients, and caused doxorubicin deposition in few samples of normal peritoneum that were examined at the end of the procedure; however, the study could not characterize how much doxorubicin was recovered as PLD or free drug. Moreover, patients recruited in the phase I study were unavoidably heterogeneous in clinical characteristics and surgical procedures, and, hence, an influence of peritonectomy procedures on PLD pharmacokinetics could not be defined (Harrison et al., 2008) .
PLD is active in both primary and recurrent ovarian cancer (Monk et al., 2010; Pujade-Lauraine et al., 2010; Pignata et al., 2011) . Recently, we launched a phase II study of intraoperative HIPEC with PLD in women with advanced primary or recurrent ovarian cancer (De Tursi et al., 2010) . This study gave us an opportunity to characterize PLD pharmacokinetics in a reasonably homogeneous set of patients and also to elucidate PLD distribution and free doxorubicin release in relation to the number of peritonectomy procedures.
Materials and Methods
Study Design. PLD pharmacokinetics were characterized during the course of a phase II study of the safety and efficacy of HIPEC in women with primary or recurrent ovarian cancer and peritoneal carcinomatosis. HIPEC was performed intraoperatively, i.e., while the patient was still in the operating room.
HIPEC was performed by the closed abdomen modality (Sugarbaker, 1999) . The perfusion circuit consisted of two Tenckhoff-type inflow drains, two outflow drains positioned in the pelvis, a heat exchanger element, and a peristaltic roller pump; abdominal and central temperatures were monitored by three abdominal thermocouple probes and an esophageal temperature probe (Fig. 1A) . Immediately after debulking surgery (including the number of peritonectomy procedures reported in figures or tables) was completed, residual peritoneal fluids were removed by vacuum suction, the abdominal wall was stitched, and the peritoneal cavity was filled with 4 liters of physiological solution at the flow rate of 2 l/min. After the abdominal wall had stretched, the outflow line was opened, and the fluid was allowed to circulate for 10 min at the flow rate of 2 l/min to stabilize intra-abdominal temperature at 42°C. Next, the outflow line was closed, the 4 liters of fluid was refilled in the abdominal cavity, and PLD (40 mg of doxorubicin/m 2 in 100 ml of 5% glucose solution) was injected over 5 min through the inflow line and allowed to equilibrate in the peritoneal cavity. Perfusion was started by opening the outflow line and was allowed to proceed for 60 min at the flow rate of 2 l/min (Fig. 1B) . At the end of HIPEC, the perfusion fluid was drained, and the peritoneal cavity was washed extensively with isotonic fluid. After the washing fluid had flowed out completely, the abdomen was reopened for inspection. Small biopsy samples of normal peritoneum or ovarian carcinomatosis were taken within 2 or 3 min. Tissue sampling was subject to technical feasibility or macroscopic evidence of residual carcinomatosis.
Inclusion criteria were age Յ75 years, World Health Organization performance status Յ2, no major cardiac or respiratory disease, normal renal and liver function, absence of extraperitoneal metastatic disease (excluding pleural effusion), and absence of ascites and biliary obstruction. In the case of recurrent cancer, an interval of at least 6 months from primary surgery (bilateral salpingo-oophorectomy) was required. Twenty-five patients met the inclusion criteria. Peritoneal perfusate and blood samples were obtained at regular times from nine patients with primary tumor and five patients with recurrent tumor; five of these patients (four with primary tumor and one with recurrent tumor) were also sampled for normal peritoneum or peritoneal carcinomatosis at post-HIPEC inspection. Three more patients with recurrent tumor were sampled for plasma only.
In the interval between clinical diagnosis of advanced tumor and debulking surgery, all patients received three cycles of systemic platinum-based neoadjuvant chemotherapy; none of the patients received conventional or liposomal doxorubicin. Debulking surgery was performed within 6 weeks after the completion of the third chemotherapy cycle . Written informed consent was obtained from all patients.
Chemicals. Pegylated liposomal doxorubicin (Caelyx) was from ScheringPlough Europe (Brussels, Belgium). Doxorubicin was obtained through the courtesy of Nerviano Medical Sciences (Milan, Italy). Other chemicals and reagents were of the highest analytical grade.
PLD and Doxorubicin Assays in Peritoneal Perfusate and Plasma. Aliquots of peritoneal perfusate were taken immediately after opening of the circuit and throughout the 1-h period of perfusion. Venous blood samples were drawn in EDTA tubes 5 min before perfusion was started (i.e., when PLD was injected through the inflow line for preperfusional equilibration in the peritoneal cavity), during perfusion, and after perfusion. Where indicated, blood samples were also obtained from three HIPEC-ineligible patients (aged 56, 67, and 72 years) who received PLD (40 mg of doxorubicin equivalents/m 2 ) by a 1-h intravenous infusion in 250 ml of 5% glucose solution. Plasma was separated by low-speed centrifugation of whole blood. All samples were stored at Ϫ20°C until they were thawed at room temperature and assayed for PLD or free doxorubicin.
Previous studies showed that organic extraction may not disrupt PLD; isopropanol evaporations, dilute acid, or acidified organic solvents disrupted PLD but were time-consuming or hydrolyzed doxorubicin to its aglycone, doxorubicinone (Chin et al., 2002) . Addition of whole samples with the nonionic detergent, Triton X-100, disrupted PLD, but an elaborate sample deproteinization was required (Chin et al., 2002) . We adopted a simple two-step procedure that involved neutral organic extraction followed by PLD disruption with Triton X-100. Then 300 l of each sample was mixed with 1.2 ml of (1:1) CHCl 3 -CH 3 OH; after low-speed centrifugation, the organic phases were combined to obtain a total extract that was used unmodified or was solubilized with a 2-fold volume of Triton X-100. Next, 100 l of unmodified or detergent-solubilized extract was subjected to reverse-phase highperformance liquid chromatography (HPLC) in a 1100 system (HewlettPackard, Palo Alto, CA). The samples were loaded onto an HxSil RP C-18 column (250 ϫ 4.6 mm, 5 m; Hamilton Company, Reno, NV), operated at 25°C and eluted at the flow rate of 1 ml/min for a total 20-min runtime [15-min linear gradient from 100% 50 mM NaH 2 PO 4 , pH 4.0, to (50%:50%) CH 3 CN-50 mM NaH 2 PO 4 , followed by a 5-min isocratic elution with (50%: 50%) CH 3 CN-50 mM NaH 2 PO 4 ]. Free or liposome-encapsulated doxorubicin was monitored fluorimetrically (excitation at 477 nm/emission at 560 nm) (Salvatorelli et al., 2006) .
In chromatograms of organic extracts of plasma samples to which known amounts of PLD or free doxorubicin had been added, PLD exhibited an irregular elution pattern characterized by a hyperfluorescent peak that preceded free doxorubicin and by two minor peaks that eluted after free doxorubicin ( Fig. 2A ). This pattern probably indicated a minor liposome heterogeneity (Gabizon et al., 1994) . Solubilization of the organic extracts with Triton X-100 did not change the retention time of free doxorubicin but made PLD release its doxorubicin content that eluted with the same retention time and fluorescence intensity as those of free doxorubicin (Fig. 2B ). Throughout this study, the organic extracts of plasma or peritoneal perfusate were therefore analyzed both unmodified and after solubilization with Triton X-100. In unmodified extracts, the presence of a single fluorescent peak at 14.6 min could indicate free doxorubicin; in solubilized extracts, the same peak could indicate total doxorubicin (PLD ϩ free doxorubicin). The difference between total doxorubicin in solubilized extracts and free doxorubicin in unmodified extracts gave a measure of PLD. The efficiency with which Triton X-100 released free doxorubicin from PLD was Ͼ95%. Triton X-100 caused a moderate quenching of free doxorubicin fluorescence at HPLC; this was obviated by plotting all measurements against standard curves built with known amounts of free doxorubicin dissolved in Triton X-100. The lowest limit of free doxorubicin detection was 0.001 M; within-day and between-day coefficients of variation were 2 and 7%, respectively. Legends to figures and tables specify whether the total doxorubicin content of a given sample consisted of PLD and/or free doxorubicin, both expressed as micromolar equivalents per liter.
HPLC assays for total doxorubicin, PLD, or free doxorubicin were validated under various conditions. First, the commercial PLD formulation used for the setup of the assay was shown to be stable at 4°C for at least 1 month, as judged from serial analyses of NaCl-diluted aliquots taken from the same stock, extracted, and subjected to HPLC with or without detergent solubilization of the organic extracts. Second, five plasma samples from HIPEC patients were refrozen after the first analysis and reassayed after one or two cycles of freezing and thawing performed over the subsequent 3 days. All such samples showed a 96 Ϯ 7.5% experimental agreement in the content of total doxorubicin, PLD, or free doxorubicin, which indicated sample stability to repeated cycles of freezing and thawing. Finally, fresh samples of plasma or peritoneal perfusate from a HIPEC patient were split in two aliquots, which were frozen and assayed within a week or after 6 months. These samples showed a Ͼ90% experimental agreement in the content of total doxorubicin, PLD, or free doxorubicin, which indicated sample stability to both short-and long-term storage.
PLD in Peritoneum and Ovarian Carcinomatosis. Small biopsy samples of normal peritoneum or peritoneal carcinomatosis (weighing 0.04 -0.3 g) were obtained at post-HIPEC inspection of the abdominal cavity. The samples were minced with scissors in ice-cold 0.3 M NaCl and disrupted by four 15-s bursts of a blade homogenizer (Ultra-Turrax; Kunkle and Janke GmbH and CokG, Staufen, Germany), followed by four strokes with a loose Teflon pestle in a Potter-Elvehjem homogenizer (Thomas Scientific, Swedesboro, NJ). In preliminary trials, homogenate extraction, solubilization, and HPLC analyses were as described for plasma or peritoneal perfusate. In these samples, total doxorubicin consisted of free doxorubicin only; however, we considered that such results could be confounded by PLD disruption that occurred during tissue homogenization and made doxorubicin appear as free drug. We performed control experiments to exclude that this was the case. In brief, a few pre-HIPEC samples of normal peritoneum were homogenized and added with known amounts of PLD; after vigorous mixing, the suspensions were rehomogenized, extracted, and analyzed by HPLC with or without detergent solubilization of the organic extracts. In these samples, total doxorubicin consisted of PLD only, which suggested that homogenization per se was unable to disrupt PLD. This was in agreement with other studies in which neither Ultra-Turrax nor Potter-Elvehjem homogenizers disrupted PLD, unless the samples were treated with acidified ethanol or Triton X-100 (Laginha et al., 2005; Cheong et al., 2006) . We concluded that post-HIPEC peritoneal biopsy samples contained free doxorubicin that had been released from PLD in vivo. After these characterizations, homogenate extraction was modified by acetone deproteinization, followed by a 10-min centrifugation at 2500 rpm; this was done to obtain clearer supernatants for HPLC analysis. Vacuum-dried supernatants were dissolved in 1 ml of CH 3 OH, and 100 l was subjected to HPLC. Doxorubicin is expressed as nanomoles per gram.
Other Details. Data were analyze by Student's t test or one-way analysis of variance followed by a Bonferroni test for multiple comparisons. Linear and nonlinear fittings, Spearman's nonparametric correlations, and PLD or free doxorubicin AUC were calculated by GraphPad Prism (version 5.00 for Windows; GraphPad Software Inc.; San Diego, CA). All values were expressed as means Ϯ S.D. Other details are given in legends for tables and figures.
Results
Patients' Characteristics. PLD pharmacokinetics were studied in 17 anthracycline-naive patients undergoing intraoperative HIPEC for primary or recurrent epithelial ovarian cancer (n ϭ 16) or ovarian sarcoma (n ϭ 1). Patients' characteristics are reported in Table 1 . It is shown that all of the patients received at least two peritonectomy procedures (pelvic peritonectomy and lesser omentectomy); 14 patients received one or more additional peritonectomy procedures (as, e.g., right or left parietal or subdiaphragmatic peritonectomy). Table 1 also reports preoperative computed tomography assessment of peritoneal cancer index (PCI), which grades the spreading of cancer cells to the peritoneum. PCI ranged from 2 to 30 versus a maximum theoretical value of 39 (Jacquet et al., 1995) . 1 Patients with primary or recurrent tumor showed no significant difference in PCI (15.7 Ϯ 8.1 versus 10.1 Ϯ 8.3, P ϭ 0.1 by unpaired Student's t test) or in the number of peritonectomy procedures (4.8 Ϯ 1.3 versus 3.8 Ϯ 1.7, P ϭ 0.09). At a cumulative analysis, the number of peritonectomy procedures performed in the two groups of patients increased with PCI, the only exception being a patient (patient 11 in Table 1 ) who received only two procedures in the face of a PCI of 25; this was caused by technical problems that limited cytoreductive surgery in that patient. Overall, the number of peritonectomy procedures correlated exponentially with PCI, both in the absence and presence of data from patient 11 [R 2 ϭ 0.807 or 0.688, SD of residuals (Sy.x) on PCI scale ϭ 5.2 or 6.5, respectively].
PLD Levels in Peritoneal Perfusate and Plasma. During HIPEC, total doxorubicin levels in peritoneal perfusate and plasma consisted of PLD only; that is, HPLC detection of free doxorubicin only occurred if the organic extracts of peritoneal perfusate or plasma had been solubilized with Triton X-100. PLD levels in peritoneal perfusate ranked Ն2 orders of magnitude higher than PLD levels in plasma; after HIPEC, PLD plasma levels decreased or remained stable over a 24-h observation period (Fig. 3) . We took aliquots of PLD prepared for injection and preperfusional 5-min equilibration in the peritoneal cavity filled with 4 liters of physiological solution. Having calculated the dilution factor, we determined that the body surface-adjusted preperfusional concentration of PLD in the peritoneal cavity (C Ϫ5 min ) averaged 30.3 Ϯ 2.6 M (range 27-36 M). In the first peritoneal perfusate sample collected after opening of the circuit, PLD concentration (C 0 ) decreased to 17.7 Ϯ 4.6 M (range 7-25 M, P Ͻ 0.001 versus C Ϫ5 min ); this early decrement of PLD, C Ϫ5 min Ϫ C 0 , will be referred to as PLD ⌬ 1 (Fig. 3, inset) . During the 1-h period of perfusion, there was an additional decrement of PLD levels in peritoneal perfusate, such that the PLD concentration in the last perfusate sample (C 60 min ) was significantly lower than C 0 (11.7 Ϯ 5.7 M, P Ͻ 0.001 versus C 0 ). This decrement, C 0 Ϫ C 60 min , will be referred to as PLD ⌬ 2 (Fig. 3, inset) .
Limited Systemic Exposure to PLD. The time course of PLD levels in peritoneal perfusate or plasma showed that patients underwent a very limited systemic exposure to PLD. To confirm this, we examined three HIPEC-ineligible patients who received the same dose of PLD by 1-h intravenous infusion in 250 ml of 5% glucose. Again, total doxorubicin levels consisted of PLD only. During infusion (30 min), at the end of infusion, or 1 h later, PLD plasma levels were, respectively, ϳ80, ϳ300, or Ͼ500 times higher than those measured at the corresponding time points in HIPEC patients (Fig. 4) .
Correlations between Peritonectomy Procedures and PLD Pharmacokinetics in Peritoneal Perfusate and Plasma. We calculated PLD peritoneal perfusate/plasma gradients as pharmacokinetic indices of PLD retention in the peritoneal cavity. During HIPEC, peritoneal perfusate/plasma gradients averaged as high as Ͼ600 for PLD peak concentration (C max ) or Ͼ1000 for PLD AUC (Ϫ5 min-1 h) (i.e., AUC measured over the period from preperfusional PLD equilibration in peritoneal cavity to completion of a 1-h perfusion). Both C max and AUC (Ϫ5 min-1 h) gradients correlated positively with the number of peritonectomy procedures performed during surgery, as if diminishing the peritoneal surface area favored PLD retention in the peritoneal cavity (Table 2 ). This finding was contrary to the notion that removing the peritoneal-plasma barrier increased the risk of drug diffusion from the peritoneal cavity in bloodstream.
We next characterized correlations between the number of peritonectomy procedures performed during surgery, PLD decrements in peritoneal perfusate during HIPEC, and plasma exposure to PLD that occurred both during and after HIPEC (AUC (Ϫ5 min-1 h) and AUC (Ϫ5 min-12 h) ) 2 . PLD plasma AUC (Ϫ5 min-1 h) and AUC (Ϫ5 min-12 h) correlated positively with PLD ⌬ 1 but not with PLD ⌬ 2 (Fig. 5, A and  B) ; on the other hand, both PLD ⌬ 1 and PLD plasma AUC (Ϫ5 min-1 h) or AUC (Ϫ5 min-12 h) correlated negatively with the number of peritonectomy procedures (Fig. 5, C and D) . These findings suggested that systemic diffusion of PLD was an early event, which occurred over the 5-min interval between injection of PLD and opening of the outflow line of the perfusion circuit (i.e., the time interval that was accompanied by PLD ⌬ 1 in peritoneal perfusate). Moreover, these findings offered additional, descriptive evidence that peritonectomy procedures increased PLD retention in the peritoneal cavity and diminished PLD diffusion in bloodstream.
Free Doxorubicin Deposition in Normal Peritoneum and Ovarian Peritoneal Carcinomatosis. Post-HIPEC samples of normal peritoneum were obtained from four patients with primary tumor and one patient with recurrent tumor. In these samples, total doxorubicin levels consisted of free doxorubicin only (i.e., the HPLC AUC of free doxorubicin was the same in unmodified or Triton X-100 solubilized extracts). In one patient with primary tumor, the levels of free doxorubicin recovered from two biopsy samples of normal peritoneum were similar to those recovered from a residual carcinomatosis nodule (Table 3) . Free doxorubicin levels seemed to vary considerably from one patient to another (cf . Table 3 ); however, they showed exponential sigmoidal correlations with PLD decrements in peritoneal perfusate and the number of peritonectomy procedures. Free doxorubicin levels correlated negatively with PLD ⌬ 1 (Fig. 6A ) but correlated positively with PLD ⌬ 2 (Fig. 6B) . Having shown that PLD ⌬ 2 occurred during the 60 min of perfusion, these results suggested that 1) PLD ⌬ 2 was a pharmacokinetic index of PLD diffusion from peritoneal perfusate in the peritoneal membrane and 2) PLD ⌬ 2 and free doxorubicin deposition seemed to be limited by PLD ⌬ 1 that occurred before starting perfusion and correlated with plasma exposure to PLD.
We next characterized whether PLD ⌬ 2 or the tissue levels of free doxorubicin correlated with the number of peritonectomy procedures. As shown in Fig. 6 , C and D, only the tissue levels of free doxorubicin correlated with the number of peritonectomy procedures. This result suggested that peritonectomy procedures did not influence PLD diffusion from peritoneal perfusate in the peritoneal membrane; however, peritonectomy procedures caused or were accompanied by effects that favored PLD degradation and free doxorubicin release in peritoneal tissue.
Discussion
Several phase III trials have been launched to define the life-saving impact of HIPEC in patients with advanced abdominopelvic malignancies (Ceelen and Flessner, 2010) ; meanwhile, the pharmacological aspects of intraperitoneal chemotherapy remain the matter of preclinical and clinical studies (Shah et al., 2009 (Shah et al., , 2011 Chambers et al., 2012; Facy et al., 2012) . We characterized the pharmacokinetics of PLD administered by intraoperative HIPEC to women with ovarian carcinomatosis. During HIPEC, peritoneal/plasma gradients of PLD averaged, respectively, ϳ600 or Ն1000 for C max or AUC (Ϫ5 min-1 h) . These values were comparable to or more than 1 order of magnitude higher than those calculated for intraperitoneally administered conventional doxorubicin (Ozols et al., 1982; Rossi et al., 2002; Sugarbaker et al., 2011) ; moreover, PLD plasma C max or AUC values always indicated that doxorubicin was safely entrapped inside the 2 PLD plasma AUC (Ϫ5 min-24 h) could not be determined accurately because of the limited number of plasma samples collected at 24 h. ) by a 1-h intravenous infusion in 250 ml of 5% glucose solution. In HIPEC patients, the first plasma samples were collected at Ϫ5 min (when PLD was injected for preperfusional equilibration in peritoneal cavity) and at 0 min (when the outflow line was opened for starting perfusion). In HIPEC-ineligible patients, the first plasma sample was collected immediately before starting infusion (0 min). Values were means Ϯ S.D.; values without vertical bars had their SD within symbols. ‫,ء‬ Ϫ5 min.
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at ASPET Journals on June 16, 2017 dmd.aspetjournals.org liposomal carrier and could not diffuse in vulnerable healthy tissues. PLD pharmacokinetics therefore showed favorable characteristics, such as good peritoneal compartmentalization of PLD and lack of systemic exposure to toxic free doxorubicin. Limited plasma exposure to PLD was also shown by the fact that during and after HIPEC, the circulating levels of PLD were ϳ80 to ϳ500 times lower than those determined in HIPEC-ineligible patients who received PLD by intravenous infusion.
PLD is characterized by a very long plasma half-life (Drummond et al., 1999) . Peritoneal compartmentalization of PLD might be counterbalanced by the long circulating time of those limited amounts of PLD that reached the bloodstream; in particular, this could generate late elevations of circulating PLD if the drug leached out of the abdominal cavity at the end of HIPEC (Harrison et al., 2008) . Our data show that an extensive post-HIPEC washing of the abdominal cavity minimizes such a risk; in fact, we did not observe post-HIPEC elevations of PLD plasma levels over a 24-h observation period.
We determined that PLD levels in peritoneal perfusate underwent two decrements. The first decrement, PLD ⌬ 1 , occurred before opening of the outflow line of the perfusion circuit; i.e., it occurred during a 5-min infusion and equilibration of PLD in the peritoneal cavity. The second decrement, PLD ⌬ 2 , occurred after opening of the outflow line to perform a 60-min perfusion.
In regard to PLD ⌬ 1 , two lines of evidence show that it was not caused by PLD dilution in pathophysiological peritoneal fluids. First, intraperitoneal injection of the perfusion medium was preceded by judicious removal of peritoneal fluids, and, second, patients with ascites were excluded from this study. Inasmuch as PLD ⌬ 1 correlated positively with PLD plasma AUC (Ϫ5 min-1 h) or AUC (Ϫ5 min-12 h) , we suggest that PLD ⌬ 1 was caused by PLD diffusing in plasma. In regard to PLD ⌬ 2 , we found that it correlated with free doxorubicin levels in post-HIPEC biopsy samples of normal peritoneum or ovarian carcinomatosis. Two lines of evidence demonstrate that PLD ⌬ 2 and peritoneal deposition of free doxorubicin were not caused by PLD destabilization in peritoneal perfusate and passive leakage of free doxorubicin. First, we never recovered free doxorubicin from peritoneal perfusate samples. Second, PLD destabilization in the perfusion medium should have caused free doxorubicin to diffuse also in plasma, but this was not the case; we never recovered free doxorubicin from plasma samples. We suggest that PLD ⌬ 2 reflected PLD diffusion from peritoneal perfusate in the peritoneal membrane, which was followed by in situ degradation of PLD and release of free doxorubicin.
Our study identifies correlations between PLD pharmacokinetics and peritonectomy procedures performed during surgery. Peritoneal perfusate/plasma gradients, indices of PLD retention in peritoneal cavity, correlated positively with the number of peritonectomy procedures; PLD ⌬ 1 and PLD plasma AUC (Ϫ5 min-1 h) or AUC (Ϫ5 min-12 h) , In peritoneal perfusate and plasma, total doxorubicin consisted of PLD only. A and B, PLD plasma AUC (Ϫ5 min-1 h) and AUC (Ϫ5 min-12 h) correlated positively with PLD ⌬ 1 in peritoneal perfusate but lacked a correlation with PLD ⌬ 2 . C and D, both PLD ⌬ 1 in peritoneal perfusate and PLD plasma AUC (Ϫ5 min-1 h) or AUC (Ϫ5 min-12 h) correlated negatively with the number of peritonectomy procedures. Data obtained from patients who, during HIPEC, were sampled for both peritoneal perfusate and plasma (coded 1-10 and 14 -17 in Table 1 ). Correlations were done by Spearman's onetailed nonparametric analyses. indices of PLD diffusion from the perfusion medium in plasma, correlated negatively with the number of peritonectomy procedures. These observations suggest that the so-called peritoneal-plasma "barrier" did not diminish but actually mediated PLD diffusion from peritoneal cavity in plasma. Having shown that PLD ⌬ 1 and plasma exposure to PLD occurred before opening of the perfusion circuit, we surmise that preperfusional stabilization of the abdominal cavity temperature at 42°C perturbed the mesothelial lining of peritoneum and favored paracellular diffusion of some PLD toward the capillary bed of the submesothelial matrix (Kouloulias et al., 2002) . Alternatively, PLD might diffuse through intercellular stomata that physiologically spot the mesothelial lining and connect tightly with lymphatic vessels (Abu-Hijleh et al., 1994) . Stomata and pore-like gap junctions of submesothelial capillaries are large enough to accommodate ϳ100-nm particles such as PLD (Abu-Hijleh et al., 1994; Fu et al., 1994; Michailova and Usunoff, 2006) . The apparent peritoneum dependence of PLD systemic diffusion denotes pharmacokinetic differences between HIPEC with PLD and conventional doxorubicin; in fact, systemic diffusion of conventional doxorubicin lacked a correlation with the number of peritonectomy procedures or showed a trend toward increasing with it (Sugarbaker et al., 2011) . It seems that doxorubicin might diffuse through abdominal and pelvic side walls (Flessner et al., 2003; de Lima Vazquez et al., 2003) .
The number of peritonectomy procedures was also shown to correlate positively with peritoneal deposition of free doxorubicin. This result did not imply that peritonectomy procedures favored PLD diffusion from peritoneal perfusate in residual peritoneal tissue; in fact, we did not observe correlations between the number of peritonectomy procedures and PLD ⌬ 2 . We suggest that the link between peritonectomy procedures and free doxorubicin deposition should be searched in tissue factors that favored PLD degradation within the peritoneal tissue. Peritoneal macrophages incorporate and degrade uncoated liposomal doxorubicin, eventually releasing free doxorubicin (Storm et al., 1988) ; however, this does not occur with PLD (Drummond et al., 1999) . PLD may nonetheless be destabilized by microenvironment changes that occur in response to tumor growth and tumor-reactive inflammation (low tissue pH, lipase secretion from dying tumor cells or inflammatory cells that accumulate in proximity to and at a distance from tumor cells) (Martin, 1998) . Our data show that the number of peritonectomy procedures correlated with PCI, which makes us surmise that peritonectomy procedures also correlated with tumor-reactive inflammation. We inspected peritoneum samples removed during surgery and found that most of them showed moderate to intense inflammation. On the other hand, it is also possible that at the moment of HIPEC, residual peritoneum hosted acute inflammation induced by tissue freshening during surgery. Inflammation induced by either mechanism could generate correlations between peritonectomy procedures and free doxorubicin deposition in residual peritoneum.
During the course of this study, one patient was sampled for post-HIPEC levels of free doxorubicin in both residual peritoneum and a carcinomatosis nodule that had escaped removal during surgery. That patient had received only two peritonectomy procedures, and, therefore, she presented with relatively low levels of free doxorubicin; nevertheless, it is worth noting that the carcinomatosis nodule and surrounding peritoneum contained comparable levels of free doxorubicin. These findings denote the pharmacological value of PLD, Peritonectomy procedures Peritonectomy procedures FIG. 6 . Correlations between PLD decrements in peritoneal perfusate, free doxorubicin levels in normal peritoneum or peritoneal ovarian carcinomatosis, and peritonectomy procedures. In peritoneal perfusate, total doxorubicin consisted of PLD only; in normal peritoneum or ovarian carcinomatosis, total doxorubicin consisted of free doxorubicin only. Tissue free doxorubicin in normal peritoneum (F) or peritoneal ovarian carcinomatosis (E) correlated negatively with PLD ⌬ 1 in peritoneal perfusate (A) but correlated positively with PLD ⌬ 2 (B). PLD ⌬ 2 in peritoneal perfusate did not correlate with the number of peritonectomy procedures (C), whereas tissue free doxorubicin did (D). The pharmacokinetics of PLD administered by HIPEC may fit in a modified three-compartment model composed of the peritoneal cavity (compartment 1), the peritoneal membrane (compartment 2), and plasma (compartment 3). Depending on the peritoneal surface area at the moment of HIPEC, compartment 2 mediated PLD diffusion from compartment 1 to 3 or made PLD degrade and release free doxorubicin in situ. Compartment 2 might therefore be split in subcompartments 2A (serving PLD diffusion in plasma) or 2B (serving PLD degradation and free doxorubicin release). Inasmuch as the apparent functions of subcompartments 2A and 2B showed opposite correlations with the number of peritonectomy procedures, plasma exposure to PLD correlated inversely with peritoneal deposition of free doxorubicin (Fig. 7) .
Our modified three-compartment model is merely descriptive; the anatomical and pathological variables of HIPEC do not allow us to build mathematically oriented kinetics. Furthermore, our model rests on multiple correlations that need to be interpreted with due caution. Cause-and-effect relationships between peritoneal surface area or pathological status and PLD pharmacokinetics can only be established by prospectively assessing patients stratified by PCI and number of peritonectomy procedures. Therefore, our results highlight an unprecedented scenario in which the pharmacokinetics of a drug administered by HIPEC may vary with the peritoneal surface area and, possibly, with its pathological status. Positive correlations between peritonectomy procedures and peritoneal deposition of active free doxorubicin should be probed vis-à-vis the notion that optimal debulking determined the efficacy of HIPEC (Verwaal et al., 2008) . Therefore, our study calls for revisiting the so-called peritoneumplasma barrier, which seems to act more dynamically than was previously believed.
New liposomal formulations have been developed to improve tumor delivery of chemotherapeutic agents. Promising results have been obtained with thermally sensitive liposomes that release doxorubicin in locally heated tumors (Lammers et al., 2008) , antibody-coated liposomes targeted to the tumor antigen CA-125 (Straubinger et al., 1988) , and folate-coated liposomes targeted to tumors that overexpress the folate receptor (Turk et al., 2004) . Our results show that in women undergoing HIPEC for advanced ovarian cancer, PLD meets the requirements for optimal drug delivery: it shows stability in the perfusion medium and diffuses marginally in the bloodstream but releases active free doxorubicin in peritoneum exposed to carcinomatosis. 
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